Company
Developer of a combination inhaled therapy targeting persistent lung infections in cystic fibrosis patients.
Every investor coverage indicates participated in a round Respirion raised.
Investors whose own portfolio pages list Respirion, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
| Brandon Capital | its portfolio page ↗ |
Companies Respirion acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Respirion. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's blog profiles Respirion, interviewing founders Barry Clements and Matt Callahan plus investment manager Helga Mikkelsen about the company's inhaled cystic fibrosis therapy, now in a Phase 2a trial.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com